TY - JOUR
T1 - Health utilities lost and risk factors associated with HPV-induced diseases in men and women: The HPV Italian collaborative study group
AU - Marcellusi, Andrea
AU - Capone, Alessandro
AU - Favato, Giampiero
AU - Mennini, Francesco Saverio
AU - Baio, Gianluca
AU - Haeussler, Katrin
AU - Bononi, Marco
AU - Crocetti, A.
AU - De Cesare, A.
AU - Miccini, M.
AU - Sapienza, P.
AU - Da Mosto, M. C.
AU - Boscolo-Rizzo, P.
AU - Stellin, M.
AU - Fuson, R.
AU - Palamara, G.
AU - Giuliani, M.
AU - Picardo, M.
AU - Panatto, D.
AU - Sasso, T.
AU - Gasparini, R.
AU - Cristoforoni, P.
AU - Di Capua, E.
AU - De Vincenzo, Rosa Pasqualina
AU - Ricci, Caterina
AU - Conte, Carmine
AU - Scambia, Giovanni
AU - Ferrandina, Maria Gabriella
PY - 2015
Y1 - 2015
N2 - Purpose: A complete economic evaluation requires accurate data concerning the resources used, outcomes, and utilities (patient's preferences) to properly value the cost utility of human papillomavirus (HPV) vaccination strategies. This study was designed to measure the utility loss in health states affected by a broad range of HPV-induced pathologies in both sexes in Italy. As a secondary objective, risk factors influencing the viral transmission and development of HPV infections were also investigated. Methods: Patients with a diagnosis of several HPV-induced pathologies including atypical squamous cells of undetermined significance (ASC-US), cervical intraepithelial neoplasia (CIN), cervical and anal-colorectal cancer, head and neck squamous cell carcinoma (HNSCC) and anogenital warts (AWs) were evaluated. Utilities, quality of life, and risk factors were elicited using a standardized and computer-guided administration of time trade-off, European Quality of Life 5 Dimensions (EQ-5D), 3 levels, and risk factor questionnaires. Utilities were measured at 6 clinical research centers across Italy. A group of healthy subjects was used as a control. A mean number of 20 healthy subjects was used as a control for each pathology group. Findings: Overall, 600 respondents were eligible for analysis: 465 patients (mean [SD] age, 44.0 [16.3] years) and 135 controls (mean [SD] age, 44.0 [13.2] years). With the exception of anal and HNSCC cancer, no statistically significant differences were observed between case and control groups, in terms of either age or quality of life at the time of interview. The patients' perception of their health condition at baseline was equal to an EQ-5D score of 0.87 (0.22). The mean (SD) value of utilities associated with the HPV-induced pathologies corresponded to 0.83 (0.24), 0.78 (0.27), 0.83 (0.22), 0.81 (0.27), 0.58 (0.31), 0.51 (0.26), and 0.69 (0.30) for ASC-US, AWs, CIN 1 (mild), CIN 2-3 (moderate to severe), cervical cancer, anal cancer and HNSCC, respectively. Utility lost due to AWs was significantly higher in females compared with males (0.71 [0.29] vs 0.83 [0.25]; P = 0.018). Having >5 sexual partners increased the risk of acquiring HPV-induced infections as much as 2.52-fold (P = 0.004), whereas for smoking or the age at start of sexual activity younger than 18 years, the risk increased by â¼ 1.62-fold (P = 0.034). High levels of education were associated with a statistically significant protective effect (P < 0.001). Implications: Risk factors and utilities elicited in this study can be used as part of future economic assessments of other HPV vaccination strategies, including an immunization program for preadolescents of both sexes in Italy.
AB - Purpose: A complete economic evaluation requires accurate data concerning the resources used, outcomes, and utilities (patient's preferences) to properly value the cost utility of human papillomavirus (HPV) vaccination strategies. This study was designed to measure the utility loss in health states affected by a broad range of HPV-induced pathologies in both sexes in Italy. As a secondary objective, risk factors influencing the viral transmission and development of HPV infections were also investigated. Methods: Patients with a diagnosis of several HPV-induced pathologies including atypical squamous cells of undetermined significance (ASC-US), cervical intraepithelial neoplasia (CIN), cervical and anal-colorectal cancer, head and neck squamous cell carcinoma (HNSCC) and anogenital warts (AWs) were evaluated. Utilities, quality of life, and risk factors were elicited using a standardized and computer-guided administration of time trade-off, European Quality of Life 5 Dimensions (EQ-5D), 3 levels, and risk factor questionnaires. Utilities were measured at 6 clinical research centers across Italy. A group of healthy subjects was used as a control. A mean number of 20 healthy subjects was used as a control for each pathology group. Findings: Overall, 600 respondents were eligible for analysis: 465 patients (mean [SD] age, 44.0 [16.3] years) and 135 controls (mean [SD] age, 44.0 [13.2] years). With the exception of anal and HNSCC cancer, no statistically significant differences were observed between case and control groups, in terms of either age or quality of life at the time of interview. The patients' perception of their health condition at baseline was equal to an EQ-5D score of 0.87 (0.22). The mean (SD) value of utilities associated with the HPV-induced pathologies corresponded to 0.83 (0.24), 0.78 (0.27), 0.83 (0.22), 0.81 (0.27), 0.58 (0.31), 0.51 (0.26), and 0.69 (0.30) for ASC-US, AWs, CIN 1 (mild), CIN 2-3 (moderate to severe), cervical cancer, anal cancer and HNSCC, respectively. Utility lost due to AWs was significantly higher in females compared with males (0.71 [0.29] vs 0.83 [0.25]; P = 0.018). Having >5 sexual partners increased the risk of acquiring HPV-induced infections as much as 2.52-fold (P = 0.004), whereas for smoking or the age at start of sexual activity younger than 18 years, the risk increased by â¼ 1.62-fold (P = 0.034). High levels of education were associated with a statistically significant protective effect (P < 0.001). Implications: Risk factors and utilities elicited in this study can be used as part of future economic assessments of other HPV vaccination strategies, including an immunization program for preadolescents of both sexes in Italy.
KW - Adult
KW - Anal cancer
KW - Anogenital warts
KW - Anus Neoplasms
KW - CIN 1
KW - CIN 2-3
KW - Carcinoma, Squamous Cell
KW - Cervical Intraepithelial Neoplasia
KW - Cervical cancer
KW - Ethnic Groups
KW - Female
KW - HPV
KW - Head and Neck Neoplasms
KW - Head and neck squamous cell carcinoma
KW - Health Status
KW - Humans
KW - Immunization Programs
KW - Italy
KW - Male
KW - Middle Aged
KW - Papillomaviridae
KW - Papillomavirus Infections
KW - Papillomavirus Vaccines
KW - Pharmacology
KW - Pharmacology (medical)
KW - Quality of Life
KW - Quality of life
KW - Risk Factors
KW - TTO
KW - Uterine Cervical Neoplasms
KW - Utilities
KW - Vaccination
KW - Adult
KW - Anal cancer
KW - Anogenital warts
KW - Anus Neoplasms
KW - CIN 1
KW - CIN 2-3
KW - Carcinoma, Squamous Cell
KW - Cervical Intraepithelial Neoplasia
KW - Cervical cancer
KW - Ethnic Groups
KW - Female
KW - HPV
KW - Head and Neck Neoplasms
KW - Head and neck squamous cell carcinoma
KW - Health Status
KW - Humans
KW - Immunization Programs
KW - Italy
KW - Male
KW - Middle Aged
KW - Papillomaviridae
KW - Papillomavirus Infections
KW - Papillomavirus Vaccines
KW - Pharmacology
KW - Pharmacology (medical)
KW - Quality of Life
KW - Quality of life
KW - Risk Factors
KW - TTO
KW - Uterine Cervical Neoplasms
KW - Utilities
KW - Vaccination
UR - http://hdl.handle.net/10807/116930
UR - http://www.elsevier.com/locate/clinthera
U2 - 10.1016/j.clinthera.2014.11.002
DO - 10.1016/j.clinthera.2014.11.002
M3 - Article
SN - 0149-2918
VL - 37
SP - 156
EP - 167
JO - Clinical Therapeutics
JF - Clinical Therapeutics
ER -